



Title	Bactericidal Activity of Mouse α -Defensin Cryptdin 4 Predominantly Affects Noncommensal Bacteria
Author(s)	Masuda, Koji; Sakai, Naoki; Nakamura, Kin'ori; Yoshioka, Sawako; Ayabe, Tokiyoshi
Citation	Journal of Innate Immunity 3(3):315-326 https://doi.org/10.1159/000322037
Issue Date	2011/04
Doc URL	http://hdl.handle.net/2115/45394
Rights	Copyright © 2011 S. Karger AG, Basel
Type	article (author version)
File Information	JIB315326.pdf



[Instructions for use](#)

1 Bactericidal Activity of Mouse α -Defensin, Cryptdin-4

2 Predominantly Affects Non-Commensal Bacteria

3
4
5 Koji Masuda^a, Naoki Sakai^{a, b}, Kiminori Nakamura^{a, b},

6 Sawako Yoshioka^a and Tokiyoshi Ayabe^{a, b, *}

7
8
9 Innate Immunity Laboratory, ^aGraduate School of Life Science,

10 ^bDepartment of Cell Biological Science, Faculty of Advanced Life Science, Hokkaido

11 University

12
13 Short title: Selective Bactericidal Activity of Cryptdin-4

14
15 * Corresponding author: Tokiyoshi Ayabe, M.D., Ph.D., Professor, Department of Cell

16 Biological Science, Graduate School of Life Science, Hokkaido University. N21, W11,

17 Kita-ku, Sapporo, Hokkaido 001-0021, Japan,

18 Tel: +81-11-706-9049, Fax: +81-11-706-9053, e-mail: ayabe@sci.hokudai.ac.jp

19

20 **Abstract**

21

22 **Mouse Paneth cell α -defensins, termed cryptdins, are secreted into the intestinal**
23 **lumen, exert microbicidal activity and contribute to the intestinal innate immunity.**

24 **Among them, cryptdin-4 (Crp4) has the most potent microbicidal activity. In the**

25 **intestinal lumen, commensal bacteria colonize and elicit beneficial effects to the**

26 **host. However, the effects of Crp4 against commensal bacteria are poorly**

27 **understood. Thus, we investigated the bactericidal activities of Crp4 against**

28 **commensal bacteria compared to non-commensal bacteria. Oxidized Crp4 showed**

29 **only minimal or no bactericidal activity against 8 out of 12 commensal bacterial**

30 **species, including *Bifidobacterium bifidum* and *Lactobacillus casei*. We further**

31 **addressed a role of the conserved disulfide bonds of Crp4 by analyzing reduced**

32 **Crp4 (r-Crp4). r-Crp4 demonstrated significantly greater bactericidal activities**

33 **against 7 of 12 commensal bacteria than did oxidized Crp4. Oxidized Crp4 and**

34 **r-Crp4 elicited equivalently potent bactericidal activities against 11 of 11**

35 **non-commensal bacteria tested such as *Salmonella enterica* serovar Typhimurium,**

36 **and 5 of 12 commensal bacteria. Furthermore, when r-Crp4 was exposed to a**

37 **processing enzyme of cryptdins, MMP-7, r-Crp4 was degraded, and bactericidal**

38 **activities disappeared. These findings suggest that Crp4 has selective bactericidal**
39 **activities against intestinal microbiota and that the activities are dependent on the**
40 **disulfide bonds.**

41

42

43 **Introduction**

44

45 Innate immunity functions as the front line of host defense in plants, invertebrates,
46 and mammals. Antimicrobial peptides (AMPs) are one of the major effectors of innate
47 immunity [1-3]. In the small intestine, antimicrobial peptide α -defensins are expressed
48 in the granules of Paneth cells and are secreted into the lumen of intestinal crypts in
49 response to bacterial stimuli [4]. The secreted α -defensins elicit potent bactericidal
50 activity and contribute to innate immunity in the small intestine [5, 6]. Mouse
51 α -defensins, termed cryptdins (Crps) are activated *in vivo* in Paneth cell granules
52 through the processing of pro-cryptdins (pro-Crps) with the proteolytic enzyme, matrix
53 metalloproteinase-7 (matrilysin, MMP-7) [7, 8]. MMP-7 cleaves pro-Crps at three
54 cleavage sites, and one of these sites is the N-terminus or near the N-terminus of mature
55 Crps [9]. This processing is an essential event for the production of mature, functional

56 Crps [7-9]. MMP-7-deficient mice that lack active form of Crps are significantly
57 susceptible to orally administered *Salmonella enterica* serovar Typhimurium than wild
58 type mice [7]. These results also show the pivotal role of AMPs in innate immunity.

59 In the gastrointestinal tract, a highly complex microbial ecosystem is constructed by
60 colonizing microbes. Hosts and microbiota have co-evolved in ways that have mutually
61 beneficial effects [10]. These include host development [11], nutritional absorption [12],
62 and functional development of the immune systems [13]. Recent studies have shown
63 that well-balanced cross-talk between the host and commensal bacteria are important
64 [14], as imbalances of the relationships result in inflammation [15] and cancer [16]. In
65 the mouse small intestine, the expression of more than 20 cryptdin genes and
66 cryptdin-related sequence genes have been reported [17-20], and these peptides are
67 secreted into the intestinal lumen where commensal bacteria reside [21]. Among Crps,
68 cryptdin-1 ~ -6 (Crp1~6) are characterized at peptide level. Although the amino acid
69 sequence identities of mature regions of Crp1~3, 6 are more than 90%, those of Crp4
70 and Crp5 with Crp1 are 42 and 54%, respectively [18]. In particular, Crp4 has several
71 features that distinguish it from other Crps. For example, the Crp4 polypeptide chain
72 uniquely lacks three amino acids between fourth and fifth cysteine residue positions
73 [18], and the unique repeated element in the region upstream of the gene transcriptional

74 start site [22]. Crp4 also has the most potent *in vitro* bactericidal activity of known
75 mouse Paneth cell α -defensins [18], suggesting that Crp4 may have pivotal role for
76 intestinal innate immunity. However, the interaction of Crp4 and small intestinal
77 microbiota is poorly understood. Thus, to clarify the effects of Crp4 on commensal
78 bacteria, we investigated the bactericidal activities of Crp4 against commensal bacteria
79 compared to non-commensal bacteria. We further tested the bactericidal activities of
80 Crp1 in addition to Crp4.

81 Crp4 is highly cationic peptide and generally believed to permeabilize bacterial
82 plasma membrane through electrostatic interaction with negatively charged bacterial
83 phospholipids followed by the insertion of hydrophobic side chains [23]. This
84 conclusion is supported by the reports which reveal that positively charged Arg residues
85 of Crp4 is critical for its bactericidal activity [24]. However, the precise mechanism(s)
86 of its bactericidal activity are not known. α -Defensins including Crp4 are characterized
87 by invariant disulfide bonds arranged between Cys¹-Cys⁶, Cys²-Cys⁴, and Cys³-Cys⁵ [3].
88 The pairings of three disulfide bonds are conserved in all species which express these
89 peptides. Previously, the bactericidal activities of the Crp4 mutants in which Cys
90 residues were substituted to Ala residues were analyzed by Maemoto *et al* [25]. They
91 showed that disulfide bond-null mutants had equivalent or greater bactericidal activity

92 than native Crp4 [25]. However, the effects of the disulfide bonds in native Crp4 on
93 bactericidal activity against commensal bacteria remain unknown. Therefore, we further
94 addressed a role of the disulfide bonds on the bactericidal activity of Crp4 using
95 reduced Crp4 (r-Crp4) which did not contain disulfide bonds.

96 Crp4 is processed by MMP-7 in the granules of Paneth cells. It was reported that
97 disulfide bonds null-mutant of Crp4 was degraded by MMP-7 [25]. This result indicates
98 that disulfide bonds of Crp4 determine proteolytic resistance to MMP-7. Therefore, to
99 elucidate the effect of reduction on the processing of r-Crp4, we also investigated the
100 susceptibility of r-Crp4 to MMP-7 and the effects of MMP-7 on the bactericidal activity
101 of the processed r-Crp4.

102

103

104 **Materials and Methods**

105

106 *Preparation of oxidized Crps and r-Crps*

107 Three pairs of disulfide bonds were introduced into Crp4 (Sigma Genosys, St. Louis,
108 MO or Medical & Biological Laboratories Co., Ltd, Nagoya, Japan) by air oxidation as
109 described [25]. Crp4 was then purified to homogeneity using reverse-phase high

110 performance liquid chromatography (RP-HPLC). The Crp4 with three pairs of disulfide
111 bonds, defined as oxidized Crp4, was purified by a C-18 column (SepaxHP-C18,
112 4.6x150 mm, 5 μ m, Sepax Technologies, Inc., Newark, DE) in 0.1% trifluoroacetic acid
113 with an 18-36% acetonitrile gradient developed over 30 min at 1 ml/min (online suppl.
114 fig. S1a). Oxidized Crp4 was obtained after final lyophilization and stored at -30°C until
115 use.

116 r-Crp4, in which the disulfide bonds were entirely reduced, was prepared. Oxidized
117 Crp4 was dissolved in 500 mM dithiothreitol (DTT), and let stand at 4°C overnight. The
118 reaction mixture was then applied to a C-18 column and r-Crp4 was purified by
119 RP-HPLC under the same condition as used in the purification of oxidized Crp4 (online
120 suppl. fig. S1b). Because the retention times of DTT and r-Crp4 were very different, we
121 conclude DTT was completely removed from r-Crp4 in the purification process. Thus,
122 r-Crp4 used in the assay did not contain DTT, and we confirmed that DTT did not affect
123 the bactericidal assay. r-Crp4 was obtained after final lyophilization and stored at -30°C
124 until use. Oxidized Crp1 and r-Crp1 were also prepared by the same respective
125 methods.

126

127 *Evaluation of disulfide bond formation*

128 Disulfide bonds formation was evaluated by Acid-Urea PAGE (AU-PAGE) [26],
129 MALDI-TOF MS, and RP-HPLC. In AU-PAGE analysis, samples (1.0 µg) of oxidized
130 Crp4 and r-Crp4 were dissolved in 5% acetic acid and electrophoresed on 12.5%
131 acrylamide gel containing 5% acetic acid and 5 M Urea at 150 V [26]. Thereafter, the
132 gel was stained with Coomassie brilliant blue R-250. Molecular masses of the peptides
133 were determined by MALDI-TOF MS (Voyager-DE PRO, Applied Biosystems,
134 Carlsbad, CA). Oxidized Crp4 and r-Crp4 were analyzed by RP-HPLC using a C-18
135 column under the same condition as used in the purification of oxidized Crp4.

136

137 *Bacterial strains and culture conditions*

138 As some of the most common commensal bacteria in the small intestine [27-30],
139 *Bifidobacterium bifidum* ATCC 11863 (*B. bifidum*), *Bifidobacterium breve* JCM 1192
140 (*B. breve*), *Bifidobacterium longum* ATCC 15707 (*B. longum*), *Lactobacillus*
141 *acidophilus* ATCC 314 (*L. acidophilus*), *Lactobacillus casei* ATCC 393 (*L. casei*),
142 *Lactobacillus johnsonii* JCM 2012 (*L. johnsonii*), *Bacteroides fragilis* JCM 11019 (*B.*
143 *fragilis*), *Bacteroides ovatus* JCM 5824 (*B. ovatus*), *Bacteroides thetaiotaomicron* JCM
144 5827 (*B. thetaiotaomicron*), *Bacteroides vulgatus* JCM 5826 (*B. vulgatus*),
145 *Enterococcus faecalis* JCM 5803 (*E. faecalis*) and *Enterococcus faecium* JCM 5804 (*E.*

146 *faecium*) were used. As examples of non-commensal bacteria in the small intestine,
147 wild-type *Salmonella enterica* serovar Typhimurium ATCC 14028 (*S. enterica* serovar
148 Typhimurium), a defensin-sensitive strain of *Salmonella enterica* serovar Typhimurium
149 *phoP*- (*S. enterica* serovar Typhimurium *phoP*-) [31], *Escherichia coli* ML35 ATCC
150 43827 (*E. coli*), *Staphylococcus aureus* ATCC 27217 (*S. aureus*), *Listeria*
151 *monocytogenes* JCM 7671 (*L. monocytogenes*), *Klebsiella oxytoca* JCM 1665 (*K.*
152 *oxytoca*), *Klebsiella pneumoniae* JCM 1662 (*K. pneumoniae*), *Proteus vulgaris* JCM
153 20013 (*P. vulgaris*), *Yersinia enterocolitica* JCM 7577 (*Y. enterocolitica*),
154 *Campylobacter coli* JCM 2529 (*C. coli*) and *Campylobacter jejuni* JCM 2013 (*C. jejuni*)
155 were used. Bacteria were cultured in the following media; *B. bifidum*: reinforced
156 clostridial medium (RCM) supplemented with 2% (w/v) of skim milk, *B. breve* and *B.*
157 *longum*: RCM, *Lactobacillus* sp.: de Man, Rogosa, and Sharpe (MRS) broth,
158 *Bacteroides* sp.: GAM broth (Nissui Seiyaku Co., Ltd., Tokyo, Japan), *Enterococcus*
159 sp.: Brain Heart Infusion (BHI), non-commensal bacteria except for *C. coli* and *C.*
160 *jejuni*: Tryptic Soy broth, *C. coli* and *C. jejuni*: GAM broth. Commensal bacteria were
161 grown in anaerobic conditions using the Anaero Pack system (Mitsubishi Gas Chemical
162 Co., Inc., Tokyo, Japan) at 37°C. Non-commensal bacteria except for *C. coli* and *C.*
163 *jejuni* were grown in a shaking incubator at 37°C with shaking at 180 rpm. *C. coli* and *C.*

164 *jejuni* were grown in microaerophilic conditions using the Anaero Pack system.

165

166 *Bactericidal peptide assay*

167 Exponential-phase bacteria cultured at 37°C were deposited by centrifugation at
168 9,300 g at 4°C for 5 min. Bacteria except for *B. vulgatus* were washed twice and
169 resuspended in Milli-Q water, *B. vulgatus* was washed twice and resuspended in PBS
170 diluted 1:4 with Milli-Q water. The OD₆₂₀ was measured to determine bacterial cell
171 numbers. Twenty µl of samples containing 1,000 colony forming units (CFU) per
172 aliquot mixed with equal vol of oxidized Crp4, r-Crp4, oxidized Crp1 or r-Crp1 to final
173 concentrations ranging from 0.027 to 1.35 µM. The mixtures were incubated for 1 hr at
174 37°C. The incubated samples were plated on RCM Agar plates for *Bifidobacterium* sp.,
175 MRS Agar plates for *Lactobacillus* sp., GAM Agar plates for *Bacteroides* sp., BHI Agar
176 plates for *Enterococcus* sp. and Tryptic Soy Agar (TSA) plates for non-commensal
177 bacteria. The plates were then incubated in anaerobic conditions at 37°C for commensal
178 bacteria or at 37°C for non-commensal bacteria. Bacterial survival rates were
179 determined from surviving colonies relative to peptide-unexposed controls (online suppl.
180 fig. S2). Bacterial cell viability of peptide-unexposed controls was not changed during
181 bactericidal peptide assay (data not shown).

182

183 *Bactericidal peptide assay against a bacterial mixture*

184 Exponential-phase *S. enterica* serovar Typhimurium, *L. casei* and *B. thetaiotaomicron*
185 cultured at 37°C were washed with Milli-Q water and each bacteria population was
186 adjusted to 150 CFU in 20 µl. Then each bacterial solution of 20 µl was mixed and the
187 mixture was incubated with 60 µl of oxidized Crp4 or r-Crp4 with the final
188 concentration of 1.35 µM. After incubation for 1 hr at 37°C, the bacterial mixtures were
189 separated and grown on TSA plates at aerobic conditions, MRS and GAM plates at
190 anaerobic conditions using the Anaero Pack system, respectively. More than 28 colonies
191 were picked randomly from each plate as a representative of total colonies, then the
192 genomic sequences of the conserved region in 16S rRNA among three species of
193 bacteria were amplified by colony direct polymerase chain reaction (PCR) using Blend
194 Taq (TOYOBO, Tokyo, Japan). The forward primer (5'-GTTGG TGAGG TAACG
195 GCTCA CCAA-3') was paired with the reverse primer (5'-TGACG GGCGG TGTGT
196 ACAAG GC-3'). The PCR products from *S. enterica* serovar Typhimurium, *L. casei*
197 and *B. thetaiotaomicron* were digested at only one site by *Bam*H I, *Bgl* II and *Spe* I,
198 respectively. Therefore, after the digestion of the PCR products by these three enzymes,
199 each bacterium was distinguished by the resulting patterns visualized by agarose

200 electrophoresis. Relative bacterial distribution was shown from picked representative
201 colonies, and the actual colony numbers of each bacterium were estimated by
202 multiplying the relative bacterial distribution by the total colony numbers. Because each
203 plate is appropriate for each bacterium, the numbers of *S. enterica* serovar Typhimurium,
204 *L. casei* and *B. thetaiotaomicron* were estimated from colonies grown on TSA, MRS
205 and GAM plates, respectively.

206

207 *Antimicrobial assay with membrane potential sensitive dye*

208 Exponential-phase bacteria were incubated in Milli-Q water at 37°C with oxidized
209 Crp4 or r-Crp4 (1.35 µM) for 1 hr. Then the suspensions were incubated for 10 min with
210 1 µg/ml of the membrane potential sensitive fluorophore, bis-(1,3-dibutylbarbituric
211 acid) trimethine oxonol [DiBAC₄(3)] (Invitrogen, Carlsbad, CA) as described [32]. The
212 suspensions were centrifuged for 5 min at 9,300 g, and the bacterial pellets were
213 resuspended in 1 ml PBS(-). Each bacterial sample was analyzed on a desktop cell
214 sorter JSAN (Bay Bioscience, Kobe, Japan). The median fluorescence intensity ratio
215 (MFIR) was obtained by dividing the median fluorescence intensity of peptide treated
216 sample by the median fluorescence intensity of non treated sample.

217

218 *Cleavage of r-Crp4 with MMP-7 in vitro*

219 Samples (1.0 µg) of oxidized Crp4 and r-Crp4 were incubated with an activated
220 recombinant human MMP-7 (1.0 µg) catalytic domain (Calbiochem, La Jolla, CA) in 10
221 mM HEPES pH 7.4, 150 mM NaCl, and 5 mM CaCl₂ for 18-24 hr at 37°C [9, 25]. The
222 digested samples were analyzed by Tris-Tricine SDS-PAGE, N-terminal peptide
223 sequencing and MALDI-TOF MS. For N-terminal peptide sequencing by Edman
224 degradation, digested r-Crp4 was resolved by RP-HPLC under the same condition as
225 used in the purification of oxidized Crp4. Fifty pmol samples of digested r-Crp4 were
226 subjected to 5 cycles of N-terminal peptide sequencing at The Creative Research
227 Initiative Sousei, Hokkaido University. To determine biological activity, the digested
228 samples were applied to bactericidal peptide assays as described above.

229

230

231 **Results**

232

233 *Oxidized Crp4 shows bactericidal activities against non-commensal bacteria, but*
234 *little or no bactericidal activity against some commensal bacteria*

235 Throughout the present study, we used oxidized Crp4 containing three pairs of

236 disulfide bonds and r-Crp4 obtained by the reduction of oxidized Crp4. As shown in the
237 results of AU-PAGE (fig. 1), MALDI-TOF MS (fig. 2a) and RP-HPLC (online suppl.
238 fig. S1a), oxidized Crp4 was homogeneous. Oxidized Crp4 showed lower molecular
239 weight than r-Crp4 by 6 Da (fig. 2), consistent with the oxidation of 6 Cys residues in
240 the formation of disulfide pairings. Furthermore, oxidized Crp4 had bactericidal activity
241 against two strains of *S. enterica* serovar Typhimurium, as well as *E. coli* and *S. aureus*
242 (fig. 3). Hence, oxidized Crp4 prepared was both biologically active and contained three
243 pairs of disulfide bonds. r-Crp4 showed reduced migration relative to oxidized Crp4 in
244 AU-PAGE (fig. 1). This corresponds to the results of AU-PAGE for oxidized Crp4
245 versus Cys-to-Ala substituted Crp4, in which the disulfide-null mutant showed reduced
246 migration compared to oxidized Crp4 [25]. MALDI-TOF MS of r-Crp4 showed a major
247 peak (fig. 2b) and RP-HPLC of r-Crp4 showed a single peak (online suppl. fig. S1b).
248 From these results, we judged r-Crp4 to be homogeneous and that the three pairs of
249 disulfide bonds were reduced. The reduction state of r-Crp4 was assured by
250 MALDI-TOF MS and AU-PAGE prior to use and after incubation in bactericidal assays.
251 Although r-Crp4 showed secondary bands in AU-PAGE suggestive of disulfide bond
252 formation, some Cys residues may tend to form disulfide bonds in AU-PAGE since an
253 excess concentration of DTT is needed for the complete reduction of Crp4.

254 Bactericidal activities of oxidized Crp4 against small intestinal commensal and
255 non-commensal bacteria were examined. Oxidized Crp4 killed 11 out of 11
256 non-commensal bacteria and 4 of 12 commensal bacteria, *B. longum*, *B. vulgatus*, *E.*
257 *faecalis* and *E. faecium* in a dose-dependent manner (fig. 3, 4c, j, k, l). In contrast,
258 oxidized Crp4 showed little or no bactericidal activities on 8 out of 12 commensal
259 bacteria, *B. bifidum*, *B. breve*, *L. acidophilus*, *L. casei*, *L. johnsonii*, *B. fragilis*, *B.*
260 *ovatus* and *B. thetaiotaomicron* at 1.35 μ M (fig. 4a, b, d, e, f, g, h, i). These activities
261 did not change at 2.7 μ M peptide concentration (data not shown). Thus, oxidized Crp4
262 had only minimal or no effect on survival of 8 out of the 12 species of commensal
263 bacteria tested. In contrast, oxidized Crp4 had potent bactericidal activities against 11 of
264 the 11 non-commensal bacterial species tested, but was only active against 4 of the 12
265 species of commensal bacteria. The statistical analysis of bactericidal activities of
266 oxidized Crp4 against commensal bacteria and non-commensal bacteria revealed that
267 oxidized Crp4 showed significantly greater bactericidal activities against
268 non-commensal bacteria than against commensals at 1.35 μ M (fig. 5, commensal
269 bacteria vs. non-commensal bacteria exposed to oxidized Crp4).

270 In the intestinal lumen, a wide variety of bacteria are able to colonize. To test the
271 selective activity of oxidized Crp4 further, a mixture of commensal and non-commensal

272 bacteria were exposed to oxidized Crp4. Oxidized Crp4 selectively killed *S. enterica*
273 serovar Typhimurium, while viability of the other commensal bacteria, *L. casei* and *B.*
274 *thetaitotaomicron* in the mixture was retained (fig. 6, non-treated and oxidized
275 Crp4-treated). This result supports the selective activities of Crp4.

276 To determine whether this selective activity is specific to oxidized Crp4, we
277 analyzed the bactericidal activities of oxidized Crp1, the most abundant Crp, against six
278 non-commensal bacteria, *S. enterica* serovar Typhimurium, *S. aureus*, *E. coli*, *L.*
279 *monocytogenes*, *K. oxytoca* and *P. vulgaris*, and six commensal bacteria, *B. bifidum*, *B.*
280 *longum*, *L. casei*, *L. johnsonii*, *B. fragilis* and *B. thetaitotaomicron*. Oxidized Crp1
281 showed potent bactericidal activities against 6 of 6 non-commensal bacteria and 1 of 6
282 commensal bacteria, *B. longum* (online suppl. table S1), however Crp1 had little or no
283 effect on 5 of 6 commensal bacteria (online suppl. table S1). Thus, oxidized Crp1 also
284 had predominant bactericidal activities against non-commensal bacteria as did oxidized
285 Crp4.

286

287 *r-Crp4 has bactericidal activities against both commensal and non-commensal*
288 *bacteria*

289 Since disulfide bond pairings in α -defensins are conserved in all species which

290 express these peptides, the bactericidal activities of r-Crp4 were analyzed to elucidate
291 the effects of the conserved disulfide bonds on its bactericidal activity. r-Crp4 showed
292 equivalent bactericidal activities against all non-commensal bacteria but only 5 of 12
293 commensal bacterial species, *B. longum*, *L. acidophilus*, *B. vulgatus*, *E. faecalis* and *E.*
294 *faecium* in comparisons with oxidized Crp4 (fig. 3, 4c, d, j, k, l). These data indicated
295 that the bactericidal activities of Crp4 against these bacteria were independent of the
296 existence of the disulfide bonds. On the other hand, r-Crp4 killed 7 out of 12
297 commensal bacteria, *B. bifidum*, *B. breve*, *L. casei*, *L. johnsonii*, *B. fragilis*, *B. ovatus*
298 and *B. thetaiotaomicron* in a dose-dependent manner and showed significantly greater
299 bactericidal activities compared to those of oxidized Crp4 (fig. 4a, b, e, f, g, h, i).
300 Therefore, the reduction of the disulfide bonds conferred Crp4 bactericidal activities
301 against *B. bifidum*, *B. breve*, *L. casei*, *L. johnsonii*, *B. fragilis*, *B. ovatus* and *B.*
302 *thetaitotaomicron*, but the disulfide bonds had little or no effect on bactericidal activity
303 against all non-commensal bacteria tested and *B. longum*, *L. acidophilus*, *B. vulgatus*, *E.*
304 *faecalis* and *E. faecium*. Comparison of bactericidal activities of oxidized Crp4 and
305 r-Crp4 revealed that r-Crp4 had significantly greater bactericidal activities against
306 commensal bacteria than those of oxidized Crp4 (fig. 5, commensal bacteria exposed to
307 oxidized Crp4 vs. r-Crp4). Bactericidal activities of oxidized Crp4 and r-Crp4 were not

308 significantly different against non-commensal bacteria (fig. 5, non- commensal bacteria
309 exposed to oxidized Crp4 vs. r-Crp4).

310 When the mixture of commensal and non-commensal bacteria was exposed to r-Crp4,
311 r-Crp4 had potent bactericidal activities against both commensals and non-commensals
312 (fig. 6, non-treated and r-Crp4-treated). Therefore, the selective bactericidal activities of
313 Crp4 against certain commensal bacteria were regulated by its disulfide bonds.

314 Furthermore, bactericidal activities of r-Crp1 against 6 non-commensal and 6
315 commensal bacteria were also tested for relative sensitivity to a second mouse
316 α -defensin, oxidized and reduced Crp1. r-Crp1 showed equivalent bactericidal activities
317 to those of oxidized Crp1 against 6 of 6 non-commensal bacteria and against 1 of 6
318 commensal bacteria, *B. longum* (online suppl. table S1), but it demonstrated
319 significantly greater bactericidal activity against 5 of 6 commensal bacteria (online
320 suppl. table S1) compared to that of oxidized Crp1. Thus, the predominant bactericidal
321 activities of Crp1 against non-commensal bacteria were also affected by its disulfide
322 bonds as in the case of Crp4.

323 We next tested membrane disruption activity of Crp4. It has been reported that Crp4
324 permeabilized bacterial cell membrane, and permeabilization correlated with bacterial
325 killing activity [23]. To examine the possible mechanism of bactericidal activities of

326 Crp4, a depolarization of the membrane potential was detected with membrane potential
327 sensitive fluoroprobe, DiBAC₄(3) [32] after exposure to oxidized and reduced Crp4.
328 r-Crp4 exhibited the significantly greater depolarization than oxidized Crp4 in 3 of 3
329 commensal bacteria tested (fig. 7). On the other hand, the depolarization activities of
330 oxidized Crp4 and r-Crp4 were not significantly different against 2 of 3 species of
331 non-commensal bacteria (fig. 7). Both oxidized and reduced Crp4 showed a remarkable
332 depolarization against *K. oxytoca* (fig. 7).

333

334 *Digestion of r-Crp4 by MMP-7 resulted in the attenuation of its bactericidal activity*

335 Crps are processed and activated by the processing enzyme, MMP-7 *in vivo* in Paneth
336 cell granules. It was reported that disulfide bonds of Crp4 are essential for proteolytic
337 resistance to MMP-7 by using disulfide bonds null-mutant of Crp4 [25]. Therefore, to
338 elucidate the susceptibility of r-Crp4 to MMP-7, an assay for proteolytic degradation
339 was conducted. Oxidized Crp4 and r-Crp4 were incubated with or without MMP-7 and
340 then applied to Tris-Tricine SDS-PAGE. r-Crp4 was digested by MMP-7 into smaller
341 fragments, whereas oxidized Crp4 showed complete resistance to MMP-7 (fig. 8a).
342 N-terminal peptide sequencing of the peptide fragment that emerged in the Tris-Tricine
343 SDS-PAGE revealed that the N-terminus was YCRKG. MALDI-TOF MS showed that

344 the peptide fragment had a molecular weight of 2480 Da. These results indicated that
345 MMP-7 cleaved r-Crp4 at Cys⁴↓Tyr⁵ and Phe²⁵↓Leu²⁶ as shown in figure 8b. Although
346 the peptide fragment appeared to have a molecular weight of ~3.5 kDa in figure 8a,
347 because the fragment comprises cationic amino acids at high rates (theoretical pI =
348 10.3), it might had a smaller migration in Tris-Tricine SDS-PAGE than that expected
349 from molecular weight determined by MALDI-TOF MS. The observed cleavage sites
350 correspond to the previous cleavage of reduced, alkylated pro-Crp4 by MMP-7 at the
351 same sites [9]. Furthermore, the digested peptide fragments were assayed for
352 bactericidal peptide activity to test for biological effects of the degradation. Previously,
353 it was shown that MMP-7 itself had no effect on bactericidal activity [7, 25]. The
354 bactericidal activities of r-Crp4 against commensal and non-commensal bacteria except
355 for *L. acidophilus* significantly decreased when r-Crp4 was digested by MMP-7 (table
356 1). In contrast, the faint bactericidal activity of digested r-Crp4 against *L. acidophilus*
357 remained (table 1). Thus, the degradation of r-Crp4 by MMP-7 attenuated its
358 bactericidal activity against most bacteria tested.

359

360

361 **Discussion**

362

363 In this study, the bactericidal activities of oxidized Crp4 against commensal and
364 non-commensal bacteria has been analyzed. Consistent with the results of previous
365 studies [18, 25], oxidized Crp4 showed potent bactericidal activities against
366 non-commensal bacteria. In contrast, oxidized Crp4 had only minimal or no bactericidal
367 activity against commensal bacteria, though it showed dose-dependent activity against *B.*
368 *longum*, *B. vulgatus*, *E. faecalis* and *E. faecium*. These results demonstrate that oxidized
369 Crp4 has more selective bactericidal activity against small intestinal bacteria. Thus, it is
370 suggested that Crp4 has a role in the regulation of intestinal microbiota by killing
371 certain non-commensal species while retaining the viability of certain commensal
372 bacteria. This concept was supported by the result that oxidized Crp4 selectively killed
373 *S. enterica* serovar Typhimurium but showed no bactericidal activity against two species
374 of commensal bacteria, *L. casei* and *B. thetaiotaomicron* when a mixture of bacterial
375 species was exposed to oxidized Crp4. Oxidized Crp1 also showed selective
376 bactericidal activities, suggesting that other members of Crps contribute to maintain
377 intestinal microbiota by killing non-commensal bacteria selectively. A recent study of
378 intestinal microbiota in MMP-7-deficient mice that lacked active form of Crps showed
379 that a significantly higher percentage of Firmicutes and a significantly lower percentage

380 of Bacteroides were detected in the small bowel of MMP-7-deficient mice compared to
381 wild-type mice [33]. Since total bacterial numbers in both mice were not changed, it
382 appears that Crps regulated the composition of the intestinal bacteria [33], consistent
383 with our results that demonstrate the selective bactericidal activity of Crp4.

384 Some commensal bacteria showed resistance to oxidized Crp4. To date, various ways
385 of bacterial resistance mechanisms against AMPs have been reported [34]. These
386 include proteolytic degradation of AMPs by microbial proteases [35], binding of
387 secreted bacterial proteins to AMPs for preventing AMPs from accessing the bacterial
388 plasma membrane [36], extruding AMPs from bacterial cell by multiple drug resistance
389 exporter [37], and modification of bacterial cell membrane to reduce the net anionic
390 charge, resulting in attenuation of the affinity of AMPs to surface membrane [38, 39]. A
391 wide variety of microbicidal mechanisms, such as the permeabilization of bacterial cell
392 membranes, and the inhibition of DNA or protein synthesis, are presented for various
393 AMPs [40]. In the case of Crp4, it was shown that Crp4 permeabilized the phospholipid
394 bilayer and that the activity was dependent on the membrane composition [41].
395 However, the precise bactericidal mechanism(s) of native Crp4 are yet to be fully
396 elucidated and may be bacteria-dependent. Therefore, the bacterial resistance
397 mechanisms against Crp4 may also be various and bacteria dependent. We detected

398 depolarization of the membrane potential in some non-commensal bacteria by Crp4.
399 Further investigation of bacterial factors that affect bactericidal activity is needed to
400 uncover the bacterial resistant mechanisms to Crp4.

401 In this study, *Bifidobacterium* sp., *Lactobacillus* sp., *Bacteroides* sp. and
402 *Enterococcus* sp. were used as types of small intestinal commensal bacteria. These
403 bacteria were reported to colonize the mouse small intestine where Crp4 is present [42,
404 43]. Oxidized Crp4 did not show bactericidal activities against *B. Bifidum*,
405 *Lactobacillus* sp., *B. thetaiotaomicron* and *B. fragilis*, while it killed *B. Longum*, *B.*
406 *vulgatus* and *Enterococcus* sp. *B. bifidum* comprises the major portion of the intestinal
407 microbiota in breast-fed infants [27]. *B. longum* is mainly found in the adult intestine
408 [28], and *L. acidophilus*, *L. casei*, *L. johnsonii*, *B. thetaiotaomicron*, *B. fragilis* and *B.*
409 *vulgatus* colonize the intestinal tract in both infants and adults [29, 30]. *Enterococcus* sp.
410 are commensal bacteria that can cause opportunistic infection. It is speculated that the
411 bacteria-dependent bactericidal activities of oxidized Crp4 against commensal bacteria
412 reflect *in vivo* regulatory role of Crp4 to tune microbial homeostasis.

413 The bactericidal activities of r-Crp4 which contained no disulfide bond against small
414 intestinal bacteria were analyzed. r-Crp4 had significantly greater bactericidal activities
415 against *B. bifidum*, *B. breve*, *L. casei*, *L. johnsonii*, *B. fragilis*, *B. ovatus* and *B.*

416 *thetaitotaomicron* than did oxidized Crp4. This result shows that the bactericidal
417 activities of Crp4 against certain commensal bacteria were regulated by a function of its
418 disulfide bonds, indicating a novel role of the conserved disulfide bonds of Crp4 in
419 controlling bactericidal activities. r-Crp4 showed significantly greater depolarization
420 activity than oxidized Crp4 against the three commensal bacterial species tested. These
421 results suggest that disruption of membrane integration may account for part of the
422 potent bactericidal activities of r-Crp4 relative to oxidized Crp4, especially with respect
423 to certain commensals. Meanwhile, r-Crp4 and oxidized Crp4 showed equivalent
424 bactericidal activities against 11 of 11 non-commensal bacteria, 5 of 12 commensal
425 bacteria. These results demonstrate that bactericidal activities of Crp4 against these
426 bacteria have no relationship with the presence of disulfide bonds. Previously, Maemoto
427 *et al* showed that the bactericidal activity of Crp4 against non-commensal bacteria was
428 independent of its disulfide array by using a disulfide-null mutant of Crp4 [25]. Our
429 results show that the reduction of disulfide bonds has the compatible effect with the
430 previous study against non-commensal bacteria. Thus, the regulatory effect of disulfide
431 bonds depends on bacterial species. r-Crp1 also showed the bacteria-dependent
432 regulatory effects of disulfide bonds. It is speculated that this property of disulfide
433 bonds may be applicable to other Crps. Native Crp4 consists of a triple-stranded

434 antiparallel β -sheet [44], whereas the NMR spectroscopy of Cys-to-Ala-substituted
435 Crp4 indicates the mutant peptide is disordered [25]. According to these structural data,
436 r-Crp4 used in this study may also have a random coil structure. In that case, it is
437 suggested that the flexibility of r-Crp4 makes it bactericidal against *B. bifidum*, *L. casei*,
438 *L. johnsonii*, *B. thetaiotaomicron* and *B. fragilis* those oxidized Crp4 did not kill
439 completely.

440 *In vitro* degradation assays revealed that r-Crp4 was digested by MMP-7. Further, the
441 bactericidal activities of r-Crp4 against small intestinal microbiota, except for *L.*
442 *acidophilus* were attenuated by this digestion. If r-Crp4 was secreted into the lumen of
443 the small intestine, r-Crp4 would kill both non-commensal and commensal bacteria,
444 resulting in the perturbation of small intestinal microbial homeostasis. Thus, it is
445 considered that degradation and inactivation of r-Crp4 before secretion would prevent
446 this perturbation. This suggests that the host has a management mechanism to avoid the
447 release of aberrant Crp4 that is disadvantageous to the host.

448 Previously, it was reported that the proform of human Paneth cell α -defensin, HD5
449 was reduced in some patients with Crohn's disease [45]. The reduced pro-HD5 was
450 degraded by trypsin, a processing enzyme of HD5 *in vivo*. This resulted in diminished
451 production of mature HD5 [45]. If Crp4 were reduced *in vivo*, degradation of Crp4 by

452 MMP-7 would lead to the dysfunction of innate immunity. Therefore, these results
453 indicated that the protease resistance of α -defensins due to the disulfide bonds may
454 contribute to the maintenance of intestinal innate immunity as well as pathology of
455 diseases such as inflammatory bowel disease.

456

457

458 **Acknowledgements**

459

460 We are grateful to Prof. A.J. Ouellette (University of Southern California) for helpful
461 discussions. This work was supported by Grant-in-Aid for Frontier Technology
462 Research from Northern Advancement Center for Science and Technology (NOASTEC)
463 of Japan (TA), a Grant-in-Aid for Knowledge Cluster Phase II, Sapporo Bio-S and a
464 Grant-in-Aid for Scientific Research on Priority Areas from The Ministry of Education,
465 Culture, Sports, Science and Technology of Japan (TA, NS). This work was also
466 partially supported by a Grant-in-Aid for Young Scientists (B) (NS) and Grant-in-Aid
467 for Scientific Research (C) (KN) from The Ministry of Education, Culture, Sports,
468 Science and Technology of Japan.

469

470

471 **References**

472

- 473 1 Zasloff M: Antimicrobial peptides of multicellular organisms. *Nature*
474 2002;415:389-395.
- 475 2 Ganz T: Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol*
476 2003;3:710-720.
- 477 3 Selsted ME, Ouellette AJ: Mammalian defensins in the antimicrobial immune
478 response. *Nat Immunol* 2005;6:551-557.
- 479 4 Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ: Secretion
480 of microbicidal α -defensins by intestinal Paneth cells in response to bacteria. *Nat*
481 *Immunol* 2000;1:113-118.
- 482 5 Ayabe T, Ashida T, Kohgo Y, Kono T: The role of Paneth cells and their
483 antimicrobial peptides in innate host defense. *Trends Microbiol* 2004;12:394-398.
- 484 6 Salzman NH, Underwood MA, Bevins CL: Paneth cells, defensins, and the
485 commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa.
486 *Semin Immunol* 2007;19:70-83.
- 487 7 Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, López-Boado YS, Stratman JL,

- 488 Hultgren SJ, Matrisian LM, Parks WC: Regulation of intestinal α -defensin
489 activation by the metalloproteinase matrilysin in innate host defense. *Science*
490 1999;286:113-117.
- 491 8 Ayabe T, Satchell DP, Pesendorfer P, Tanabe H, Wilson CL, Hagen SJ, Ouellette
492 AJ: Activation of Paneth cell α -defensins in mouse small intestine. *J Biol Chem*
493 2002;277:5219-5228.
- 494 9 Shirafuji Y, Tanabe H, Satchell DP, Henschen-Edman A, Wilson CL, Ouellette AJ:
495 Structural determinants of procryptdin recognition and cleavage by matrix
496 metalloproteinase-7. *J Biol Chem* 2003;278:7910-7919.
- 497 10 Dethlefsen L, McFall-Ngai M, Relman DA: An ecological and evolutionary
498 perspective on human-microbe mutualism and disease. *Nature* 2007;449:811-818.
- 499 11 Koropatnick TA, Engle JT, Apicella MA, Stabb EV, Goldman WE, McFall-Ngai
500 MJ: Microbial factor-mediated development in a host-bacterial mutualism. *Science*
501 2004;306:1186-1188.
- 502 12 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An
503 obesity-associated gut microbiome with increased capacity for energy harvest.
504 *Nature* 2006;444:1027-1031.
- 505 13 Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory

506 molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*
507 2005;122:107-118.

508 14 Artis D: Epithelial-cell recognition of commensal bacteria and maintenance of
509 immune homeostasis in the gut. *Nat Rev Immunol* 2008;8:411-420.

510 15 Mazmanian SK, Round JL, Kasper DL: A microbial symbiosis factor prevents
511 intestinal inflammatory disease. *Nature* 2008;453:620-625.

512 16 Karin M, Lawrence T, Nizet V: Innate immunity gone awry: linking microbial
513 infections to chronic inflammation and cancer. *Cell* 2006;124:823-835.

514 17 Ouellette AJ, Lualdi JC: A novel mouse gene family coding for cationic,
515 cysteine-rich peptides. Regulation in small intestine and cells of myeloid origin. *J*
516 *Biol Chem* 1990;265:9831-9837.

517 18 Ouellette AJ, Hsieh MM, Nosek MT, Cano-Gauci DF, Huttner KM, Buick RN,
518 Selsted ME: Mouse Paneth cell defensins: primary structures and antibacterial
519 activities of numerous cryptdin isoforms. *Infect Immun* 1994;62:5040-5047.

520 19 Hornef MW, Putsep K, Karlsson J, Refai E, Andersson M: Increased diversity of
521 intestinal antimicrobial peptides by covalent dimer formation. *Nat Immunol*
522 2004;5:836-843.

523 20 Patil A, Hughes AL, Zhang G: Rapid evolution and diversification of mammalian

524 α -defensins as revealed by comparative analysis of rodent and primate genes.
525 *Physiol Genomics* 2004;20:1-11.

526 21 Mastroianni JR, Ouellette AJ: α -defensins in enteric innate immunity: functional
527 Paneth cell α -defensins in mouse colonic lumen. *J Biol Chem*
528 2009;284:27848-27856.

529 22 Ouellette AJ, Darmoul D, Tran D, Huttner KM, Yuan J, Selsted ME: Peptide
530 localization and gene structure of cryptdin 4, a differentially expressed mouse
531 Paneth cell α -defensin. *Infect Immun* 1999;67:6643-6651.

532 23 Satchell DP, Sheynis T, Kolusheva S, Cummings J, Vanderlick TK, Jelinek R,
533 Selsted ME, Ouellette AJ: Quantitative interactions between cryptdin-4 amino
534 terminal variants and membranes. *Peptides* 2003;24:1795-1805.

535 24 Tanabe H, Qu X, Weeks CS, Cummings JE, Kolusheva S, Walsh KB, Jelinek R,
536 Vanderlick TK, Selsted ME, Ouellette AJ: Structure-activity determinants in Paneth
537 cell α -defensins: loss-of-function in mouse cryptdin-4 by charge-reversal at arginine
538 residue positions. *J Biol Chem* 2004;279:11976-11983.

539 25 Maemoto A, Qu X, Rosengren KJ, Tanabe H, Henschen-Edman A, Craik DJ,
540 Ouellette AJ: Functional analysis of the α -defensin disulfide array in mouse
541 cryptdin-4. *J Biol Chem* 2004;279:44188-44196.

- 542 26 Selsted ME, Brown DM, DeLange RJ, Lehrer RI: Primary structures of MCP-1 and
543 MCP-2, natural peptide antibiotics of rabbit lung macrophages. J Biol Chem
544 1983;258:14485-14489.
- 545 27 Weiss JE, Rettger LF: *Lactobacillus bifidus*. J Bacteriol 1934;28:501-521.
- 546 28 Reuter G: Designation of type strains for *Bifidobacterium* species. Int J Syst
547 Bacteriol. 1971;21:273-275.
- 548 29 Dellaglio F, Bottazzi V, Vescovo M: Deoxyribonucleic acid homology among
549 *Lactobacillus* species of the subgenus *Streptobacterium* Orla-Jensen. Int J Syst
550 Bacteriol. 1975;25:160-172.
- 551 30 Hansen PA, Mocquot G: *Lactobacillus acidophilus* (Moro) comb. nov. Int J Syst
552 Bacteriol. 1970;20:325-327.
- 553 31 Fields PI, Groisman EA, Heffron F: A *Salmonella* locus that controls resistance to
554 microbicidal proteins from phagocytic cells. Science 1989;243:1059-1062.
- 555 32 Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF: A flow cytometric
556 assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J
557 Microbiol Methods 2006;65:335-345.
- 558 33 Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Tegatz P,
559 Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock

- 560 GM, Bevins CL, Williams CB, Bos NA: Enteric defensins are essential regulators
561 of intestinal microbial ecology. Nat Immunol 2010;11:76-83.
- 562 34 Peschel A, Sahl HG: The co-evolution of host cationic antimicrobial peptides and
563 microbial resistance. Nat Rev Microbiol 2006;4:529-536.
- 564 35 Guina T, Yi EC, Wang H, Hackett M, Miller SI: A PhoP-regulated outer membrane
565 protease of *Salmonella enterica* serovar Typhimurium promotes resistance to
566 alpha-helical antimicrobial peptides. J Bacteriol 2000;182:4077-4086.
- 567 36 Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A: *Staphylococcus*
568 *aureus* resists human defensins by production of staphylokinase, a novel bacterial
569 evasion mechanism. J Immunol 2004;172:1169-1176.
- 570 37 Shafer WM, Qu X, Waring AJ, Lehrer RI: Modulation of *Neisseria gonorrhoeae*
571 susceptibility to vertebrate antibacterial peptides due to a member of the
572 resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA
573 1998;95:1829-1833.
- 574 38 Guo L, Lim KB, Poduje CM, Daniel M, Gunn JS, Hackett M, Miller SI: Lipid A
575 acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell
576 1998;95:189-198.
- 577 39 Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H,

578 Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KP, van Strijp JA:
579 *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil
580 killing via the novel virulence factor MprF is based on modification of membrane
581 lipids with l-lysine. J Exp Med 2001;193:1067-1076.

582 40 Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in
583 bacteria? Nat Rev Microbiol 2005;3:238-250.

584 41 Hadjicharalambous C, Sheynis T, Jelinek R, Shanahan MT, Ouellette AJ, Gizeli E:
585 Mechanisms of α -defensin bactericidal action: comparative membrane disruption
586 by cryptdin-4 and its disulfide-null analogue. Biochemistry 2008;47:12626-12634.

587 42 Wagner RD, Warner T, Roberts L, Farmer J, Balish E: Colonization of congenitally
588 immunodeficient mice with probiotic bacteria. Infect Immun 1997;65:3345-3351.

589 43 Ménard O, Butel M, Gaboriau-Routhiau V, Waligora-Dupriet A: Gnotobiotic mouse
590 immune response induced by *Bifidobacterium* sp. strains isolated from infants. Appl
591 Environ Microbiol 2008;74:660-666.

592 44 Jing WG, Hunter HN, Tanabe H, Ouellette AJ, Vogel HJ: Solution structure of
593 cryptdin-4, a mouse Paneth cell α -defensin. Biochemistry 2004;43:15759-15766.

594 45 Tanabe H, Ayabe T, Maemoto A, Ishikawa C, Inaba Y, Sato R, Moriichi K,
595 Okamoto K, Watari J, Kono T, Ashida T, Kohgo Y: Denatured human α -defensin

596 attenuates the bactericidal activity and the stability against enzymatic digestion.

597 Biochem Biophys Res Commun 2007;358:349-355.

598

599

600

601 **Figure Legends**

602

603 **Fig. 1.** AU-PAGE analysis of oxidized Crp4 and r-Crp4. Samples (1.0 µg) of oxidized
604 Crp4 and r-Crp4 were resolved by AU-PAGE (12.5% acrylamide gel containing 5%
605 acetic acid and 5 M Urea) and then stained with Coomassie brilliant blue R-250.

606

607 **Fig. 2.** MALDI-TOF MS analysis of oxidized Crp4 and r-Crp4. Molecular weights of
608 oxidized Crp4 and r-Crp4 analyzed by MALDI-TOF MS are shown in (a) and (b),
609 respectively.

610

611 **Fig. 3.** Bactericidal activities of oxidized Crp4 and r-Crp4 against non-commensal
612 bacteria. Survival rates of *S. enterica* serovar Typhimurium (a), *S. enterica* serovar
613 Typhimurium *phoP*- (b), *E. coli* ML35 (c), *S. aureus* (d), *L. monocytogenes* (e), *K.*

614 *oxytoca* (**f**), *K. pneumoniae* (**g**), *P. vulgaris* (**h**), *Y. enterocolitica* (**i**), *C. coli* (**j**) and *C.*
615 *jejuni* (**k**) exposed to oxidized Crp4 (●) or r-Crp4 (□) at 0.027, 0.054, 0.135, 0.27 and
616 1.35 μM are shown. Data were expressed as the means ± S.E., n = 6 for **a**, **b**, **c** and **d**, n
617 = 3 for **e**, **f**, **g**, **h**, **i**, **j** and **k** performed in triplicate.

618

619 **Fig. 4.** Bactericidal activities of oxidized Crp4 and r-Crp4 against commensal bacteria.
620 Survival rates of *B. bifidum* (**a**), *B. breve* (**b**), *B. longum* (**c**), *L. acidophilus* (**d**), *L. casei*
621 (**e**), *L. johnsonii* (**f**), *B. fragilis* (**g**), *B. ovatus* (**h**), *B. thetaiotaomicron* (**i**), *B. vulgatus* (**j**),
622 *E. faecalis* (**k**) and *E. faecium* (**l**) exposed to oxidized Crp4 (●) or r-Crp4 (□) at 0.027,
623 0.054, 0.135, 0.27 and 1.35 μM are shown. Data were expressed as the means ± S.E., n
624 = 6 for **a**, **c**, **d**, **e**, **i** and **j**, n = 3 for **b**, **f**, **g**, **h**, **k** and **l** performed in triplicate, **P* < 0.01 by
625 Student's *t* test.

626

627 **Fig. 5.** Statistical analysis of bactericidal activities. Survival rates of 12 commensal
628 bacteria and 11 non-commensal bacteria (Material and Methods) exposed to oxidized
629 Crp4 or r-Crp4 at 1.35 μM are shown. Each point represents a survival rate of each
630 bacterium. The medians were expressed as horizontal lines; the data were evaluated for
631 statistical significance by Mann-Whitney U test, where differences at values of **P* <

632 0.05 were considered to be significant. NS: Not significant.

633

634 **Fig. 6.** Bactericidal activities of oxidized Crp4 and r-Crp4 against the mixture of
635 commensal and non-commensal bacteria. The bacterial mixture of exponentially
636 growing *S. enterica* serovar Typhimurium as non-commensal bacteria, *L. casei* and *B.*
637 *thetaitotaomicron* as commensal bacteria were exposed to oxidized Crp4 or r-Crp4 at
638 1.35 μ M. Surviving bacteria were counted as colony forming units.

639

640 **Fig. 7.** Antimicrobial assay with membrane sensitive dye. The median fluorescence
641 intensity ratio (MFIR) of commensal bacteria (**a**) and non-commensal bacteria (**b**)
642 exposed to oxidized Crp4 (\blacksquare) or r-Crp4 (\square) are shown. Data were expressed as the
643 means \pm S.E. performed in triplicate, and evaluated for statistical significance by
644 Student's *t* test, where differences at values of $*P < 0.05$ were considered to be
645 significant. NS: Not significant.

646

647 **Fig. 8.** Proteolytic degradation assay of oxidized Crp4 and r-Crp4 by MMP-7. **a**
648 Tris-Tricine SDS-PAGE analysis of oxidized Crp4 and r-Crp4 incubated with or without
649 MMP-7. Samples (1.0 μ g) of oxidized Crp4 and r-Crp4 were incubated with or without

650 MMP-7 (1.0 μg) catalytic domain. The digested samples were analyzed by Tris-Tricine
651 SDS-PAGE. The positions of bands corresponding to MMP-7 and Crp4 are noted at the
652 *right*. The *bold arrow* denotes the position of the MMP-7-digested fragment of r-Crp4.
653 **b** MMP-7 cleavage sites in r-Crp4. The digested r-Crp4 was analyzed by 5 cycles of
654 N-terminal peptide sequencing and MALDI-TOF MS. Cleavage sites are noted by
655 *downwards arrows* (↓). *Numerals* below the r-Crp4 sequence refer to residue positions
656 in reference to the N-terminal Gly of r-Crp4 as residue position number 1.

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671 **Table**

672

Table1. Bactericidal activities of r-Crp4 and MMP-7-digested r-Crp4

<i>Bacteria</i>	Survival rates (%) ^a of bacteria exposed to:	
	r-Crp4	MMP-7-digested r-Crp4
<i>S. enterica</i> serovar Typhimurium	1.4 ± 1.2	98.3 ± 9.9*
<i>S. enterica</i> serovar Typhimurium <i>phoP</i> -	3.2 ± 2.7	96.3 ± 12.0*
<i>E. coli</i> ML35	0.0 ± 0.0	118.1 ± 10.9*
<i>S. aureus</i>	0.0 ± 0.0	49.5 ± 13.4*
<i>B. bifidum</i>	13.1 ± 7.3	96.4 ± 10.4*
<i>B. longum</i>	0.2 ± 0.2	87.3 ± 17.0*
<i>L. casei</i>	28.8 ± 7.3	72.4 ± 10.3*
<i>L. acidophilus</i>	53.9 ± 6.3	64.8 ± 0.9 [‡]
<i>B. thetaiotaomicron</i>	33.9 ± 5.7	86.5 ± 9.5*
<i>B. vulgatus</i>	13.6 ± 6.6	101.6 ± 8.9*

673 ^a Values are means ± S.E., for survival rates of bacteria exposed to r-Crp4 (1.35 μM)
674 and MMP-7-digested r-Crp4 (1.35 μM). n = 6 for r-Crp4, n = 3 for MMP-7-digested
675 r-Crp4.

676 *Value is significantly different (*P* < 0.01) compared to that exposed to r-Crp4 as
677 calculated by Student's *t* test.

678 [‡]Not significant.

679

680

681

682

683

684
685
686
687
688
689

Online Supplementary

Online supplementary Table S1. Bactericidal activities of oxidized Crp1 and r-Crp1

<i>Bacteria</i>	Survival rates (%) ^a of bacteria exposed to:	
	Oxidized Crp1	r-Crp1
<i>Commensal bacteria</i>		
<i>B. bifidum</i>	97.7 ± 5.2	0 ± 0*
<i>B. longum</i>	0 ± 0	0 ± 0‡
<i>L. casei</i>	71.1 ± 7.8	0 ± 0*
<i>L. johnsonii</i>	73.5 ± 13.0	0 ± 0*
<i>B. fragilis</i>	66.8 ± 6.2	15.1 ± 7.0*
<i>B. thetaiotaomicron</i>	89.8 ± 3.9	4.0 ± 8.1*
<i>Non-commensal bacteria</i>		
<i>S. enterica</i> serovar Typhimurium	1.5 ± 0.5	1.9 ± 1.3‡
<i>S. aureus</i>	0 ± 0	0 ± 0‡
<i>E. coli</i>	11.0 ± 2.1	0 ± 0‡
<i>L. monocytogenes</i>	24.5 ± 8.0	10.0 ± 3.1‡
<i>K. oxytoca</i>	0 ± 0	0 ± 0‡
<i>P. vulgaris</i>	7.9 ± 2.0	1.0 ± 0.4‡

690 ^a Values are means ± S.E., for survival rates of bacteria exposed to oxidized Crp1 or
691 r-Crp1 (1.35 μM) performed in triplicate.

692 *Value is significantly different ($P < 0.01$) compared to that exposed to oxidized Crp1
693 as calculated by Student's *t* test.

694 ‡Not significant.

695
696

697

698

699 **Online Supplementary Fig. S1.** Purification of oxidized Crp4 and r-Crp4 by RP-HPLC.

700 Oxidized Crp4 (**a**) and r-Crp4 (**b**) were purified by a C-18 column (SepaxHP-C18,

701 4.6x150 mm, 5 μ m, Sepax Technologies, Inc., Newark, DE) in 0.1% trifluoroacetic acid

702 with an 18-36% acetonitrile gradient developed over 30 min at 1 ml/min.

703

704 **Online Supplementary Fig. S2.** Bactericidal peptide assay. The colonies of *Salmonella*

705 *enterica* serovar Typhimurium incubated with oxidized Crp4 are shown as a represented

706 example. Exponential-phase bacteria cultured at 37°C were washed and the bacteria

707 populations were adjusted to 1,000 CFU in 20 μ l. Then the bacteria solution was mixed

708 with equivalent volumes of oxidized Crp4 with the final concentrations of 0.027, 0.054,

709 0.135, 0.27, and 1.35 μ M. The mixtures were plated after incubation for 1 hr at 37°C.

710 The assay measured bactericidal activity because the peptides affect bacteria only at the

711 incubation time. Bacteria survival rates were determined from the numbers of surviving

712 colonies relative to peptide-unexposed controls.




Fig. 1. Koji Masuda




Fig. 2. Koji Masuda




Fig. 3. Koji Masuda




Fig. 4. Koji Masuda




Fig. 7. Koji Masuda




Fig. 8. Koji Masuda